CM
MRTX

Castleark Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Castleark Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-24,560
Closed -$1.72M – 329
2022
Q3 		$1.72M Buy
+24,560
New +$1.82M 0.1% 165
2021
Q1 		– Sell
-25,918
Closed -$5.69M – 381
2020
Q4 		$5.69M Sell
25,918
-20,510
-44% -$4.43M 0.21% 129
2020
Q3 		$7.71M Sell
46,428
-132
-0.3% -$18.1K 0.3% 101
2020
Q2 		$5.32M Sell
46,560
-520
-1% -$50.4K 0.23% 118
2020
Q1 		$3.62M Buy
+47,080
New +$4.22M 0.21% 127

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Castleark Management's MRTX Position: Q4 2022 in Review

Castleark Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2022, closing a stake of 24,560 shares — an estimated $1.72M sold.

Castleark Management first reported a position in MRTX in Q1 2020 and held it in 5 quarters. The position peaked at $7.71M in Q3 2020. 233 funds tracked by Wall St. Rank hold MRTX as of Q4 2022.

  • Castleark Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Castleark Management sold 24,560 Mirati Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $1.72M.
  • Castleark Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2020 and held it in 5 quarters.
  • Castleark Management's Mirati Therapeutics, Inc. Common Stock position peaked at $7.71M in Q3 2020.
  • 233 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Castleark Management's 13F filing for Q4 2022, filed 10 Feb 2023.